Core Viewpoint - The company, Hangya Technology, plans to establish subsidiaries in Singapore and Malaysia with an investment of up to $70 million (approximately 500 million RMB) to optimize its strategic layout and expand overseas market operations, enhancing its overall competitiveness [2][3]. Group 1: Investment Details - The investment will not constitute a related party transaction or a major asset restructuring [3]. - The subsidiaries will primarily engage in investment management, import-export trade, and the research, production, and sales of aerospace engine components and medical orthopedic implants [3]. Group 2: Company Background - Hangya Technology was founded on January 30, 2013, with a registered capital of 258.38 million RMB, and is headquartered in Wuxi [3]. - The company specializes in the R&D, production, and sales of key components for aerospace engines and gas turbines, as well as medical orthopedic implants [3]. Group 3: Financial Performance - The company's revenue for 2022, 2023, 2024, and the first three quarters of 2025 was 363 million RMB, 544 million RMB, 703 million RMB, and 530 million RMB, reflecting year-on-year growth rates of 15.95%, 49.93%, 29.39%, and 1.95% respectively [4]. - The net profit attributable to the parent company for the same periods was 20.06 million RMB, 90.20 million RMB, 127 million RMB, and 77.87 million RMB, with year-on-year growth rates of -17.34%, 349.61%, 40.27%, and -16.04% respectively [4]. - The company's asset-liability ratios for the same periods were 30.59%, 31.28%, 38.33%, and 38.77% [4].

Core Viewpoint - The company, Wuxi Hyatech Co., Ltd., plans to establish a subsidiary in Singapore and a subsidiary in Malaysia with an investment of up to $70 million, aiming to enhance its strategic layout and competitiveness in the global market [2][4]. Group 1: Investment Overview - The company intends to set up "Hyatech Investments Singapore PTE. LTD." in Singapore and "Hyatech (Malaysia) SDN. BHD." in Malaysia, with a total investment not exceeding $70 million (approximately 500 million RMB) [2][4]. - The investment will be funded through the company's own resources, and the actual investment amount will depend on approvals from Chinese and local authorities [2][4]. Group 2: Decision and Approval Process - The investment proposal was approved during the fourth board meeting held on November 28, 2025, and does not require shareholder approval as it falls within the board's decision-making authority [5]. Group 3: Purpose and Impact of Investment - The investment aims to deepen strategic cooperation with international clients and integrate into the global supply chain of the aviation and medical orthopedic industries, enhancing the company's market competitiveness and risk resilience [9][10]. - The company's current financial status is stable, and the investment is expected to positively impact its long-term strategic planning and operational development, thereby strengthening its market share in the global aviation and medical sectors [10].

Group 1 - SMIC announced the termination of the sale of its stake in SMIC Ningbo due to failure to reach an agreement within the expected timeframe, retaining a 14.832% stake post-termination, with no significant impact on financial status [2] - Chaozhuo Aerospace's actual controller will change to Hubei State-owned Assets Supervision and Administration Commission, with stock resuming trading on December 1 [2] - ST Lifan faces potential forced delisting due to false disclosures in its 2021-2023 annual reports, with a total false revenue of 592 million yuan, representing 50.91% of the reported revenue for those years [3] Group 2 - Lijun Holdings' subsidiary signed a contract worth approximately 57.6 million USD for high-pressure roller mills, accounting for 52.53% of the audited consolidated revenue for 2024, expected to positively impact future performance [3] - Sanjiang Shopping's second-largest shareholder, Alibaba Zeta, reduced its stake by 5.4768 million shares, decreasing its holding from 30% to 29% [4] - Tianfeng Securities is under investigation by the CSRC for suspected information disclosure violations and illegal financing [5] Group 3 - China Jushi's major shareholder, Zhenstone Group, plans to increase its stake by no less than 550 million yuan and no more than 1.1 billion yuan [6] - Helun Zhe's major shareholder received a notice of investigation for suspected information disclosure violations, which does not affect the company's operations [7] - Yongtai Energy's actual controller also received a notice of investigation for similar violations, with no impact on the company's operations [8] Group 4 - Wuhantian Source's major shareholder, Konka Group, plans to transfer 9.83% of its shares to China Resources Asset Management [9] - Pinggao Electric won a bid for a State Grid project worth approximately 773 million yuan [9] - Zhejiang Longsheng is collaborating with a private equity fund to establish a venture capital partnership [9]

Key Points - Guizhou Moutai elected Chen Hua as the chairman of the fourth board of directors and plans to repurchase shares between RMB 1.5 billion and RMB 3 billion [1] - Tianfeng Securities is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure and illegal financing [1] Share Buybacks - Demai Technology raised the upper limit for share repurchase to RMB 45 per share [5] - Jianbang Technology plans to repurchase shares worth between RMB 15 million and RMB 30 million [5] - Huayuan Holdings intends to repurchase shares worth between RMB 30 million and RMB 60 million [5] Major Investments - Jinling Pharmaceutical plans to invest RMB 893 million in hospital expansion projects [7] - Dongfang Mingzhu intends to invest approximately RMB 500 million to establish a partnership and acquire part of the equity of New H3C [7] - Chang'an Automobile aims to establish a robotics company to develop innovative products and solutions [7] Mergers and Acquisitions - Kaizhong Co. plans to acquire 60% of Anhui Tuosheng's equity, with stock resuming trading on December 1 [7] - Youa Co. has resumed the review process for issuing shares and cash to purchase assets [7] - Jiasheng Technology intends to acquire controlling interest in Shudun Information Technology Co., with stock continuing to be suspended [7] Financing Activities - Shenzhen Energy plans to apply for a public bond issuance with a total scale not exceeding RMB 20 billion [7] - Huakong Saige has terminated its specific object stock issuance [7]

Core Viewpoint - The company, Hangya Technology, plans to establish a subsidiary in Singapore and a wholly-owned subsidiary in Malaysia with an investment of up to $70 million (approximately 500 million RMB) to enhance strategic cooperation with international clients and integrate into the global aviation and medical orthopedic supply chains [1] Group 1: Investment and Expansion - The Singapore subsidiary will focus on investment management and import-export trade, while the Malaysian subsidiary will engage in the R&D, production, and sales of aerospace engine components and medical orthopedic implants [1] - This investment is aimed at getting closer to international markets, enhancing nearshore R&D and production in Southeast Asia, and effectively responding to global supply chain challenges [1] Group 2: Financial Performance and Business Strategy - In 2024, the company's international business revenue is expected to reach 376 million RMB, a year-on-year increase of 35.05%, accounting for over 50% of total revenue [2] - The company maintains a balanced market strategy between domestic and international markets, with stable revenue structure and reasonable fluctuations in income proportions [2] Group 3: Product Development and Market Position - Hangya Technology is a major supplier of low-pressure compressor blades for the French Safran Group, holding a global market share of no less than 50% in the LEAP engine series [2] - The company has been expanding its high-value-added high-pressure compressor blade business overseas since 2018, with expectations for an increasing proportion of high-pressure blades in its product structure [2] Group 4: Future Growth and Competitive Landscape - The company is focusing on overseas growth in its medical orthopedic implant business, having established long-term strategic partnerships with two leading international medical device manufacturers [3] - The international aviation market is in a recovery and structural adjustment phase, which is favorable for deepening strategic partnerships with core international clients [3]

Group 1 - Jianbang Co., Ltd. plans to repurchase shares using self-owned funds between 15 million and 30 million yuan, with a maximum price of 38 yuan per share [1] - Yatong Precision Engineering's investment in a private equity fund has been terminated due to failure to complete the agreed investment, leading to the fund's dissolution [1] - China Storage Co., Ltd. intends to invest 1.129 billion yuan in the Sanjiang Port project, with its wholly-owned subsidiary contributing 500 million yuan to establish a project company [2] Group 2 - Guangxin Co., Ltd. plans to inject assets worth 4.383 billion yuan into its wholly-owned subsidiary, increasing its registered capital from 10 million to 20 million yuan [3] - Jiangxin Home plans to use up to 3 billion yuan of idle self-owned funds for cash management in low-risk financial products [4] - Huangshan Tourism intends to lease part of the Huangshan scenic area for 1.27 billion yuan over a 10-year period [5] Group 3 - Jilin Expressway's general manager has resigned due to work adjustments [6] - Guoyao Modern's subsidiary has received a drug registration certificate for hydromorphone hydrochloride injection, suitable for pain management [8] - Hangya Technology plans to invest up to 70 million USD to establish subsidiaries in Singapore and Malaysia [10] Group 4 - ST Sailong's subsidiary has received approval for the listing of two chemical raw materials [11] - Shanghai Pharmaceuticals' tramadol hydrochloride injection has passed the consistency evaluation for generic drugs [12] - Yubang Electric has obtained a laboratory accreditation certificate from CNAS, indicating its testing capabilities [14] Group 5 - ST Lifang's stock will be subject to delisting risk warning starting December 1 due to administrative penalties [15] - Zhejiang Longsheng is investing 200 million yuan in a private equity partnership focused on high-potential enterprises [15] - Huayang Co., Ltd.'s subsidiary has obtained safety production permits, allowing it to commence production [16] Group 6 - Xujie Electric has won a bid for a State Grid project worth 1.518 billion yuan [17] - Pinggao Electric and its subsidiaries have collectively won a State Grid project worth approximately 773 million yuan [17] - ST Lanhua's subsidiary has entered the trial production phase for a juice beverage project with a total investment of up to 65 million yuan [18] Group 7 - Huakong Saige has terminated its stock issuance plan due to various considerations [19] - Yatong Co., Ltd. plans to invest 36 million yuan to establish a joint venture in renewable energy [20] - Warner Pharmaceuticals has received a drug registration certificate for a new inhalation solution for COPD patients [21] Group 8 - Demais has raised the upper limit for its share repurchase price to 45 yuan per share [22] - China West Electric's subsidiaries have collectively won a State Grid procurement project worth approximately 2.98 billion yuan [22] - Changan Automobile's joint venture has submitted a listing application to the Hong Kong Stock Exchange [23] Group 9 - Yinlun Co., Ltd. plans to invest approximately 133 million yuan to acquire a controlling stake in Shenzhen Deep Blue Electronics [24] - Zhongfu Information intends to increase its wholly-owned subsidiary's capital by 380 million yuan [24] - Financial Street's major shareholder has reduced its stake by 0.25% [25] Group 10 - Audiwei has formally submitted an application for H-share listing [26] - Zhongcai Technology's private placement application has been accepted by the Shenzhen Stock Exchange [27] - Haowei Group's subsidiary plans to invest 200 million yuan in a private equity fund focused on semiconductor investments [28] Group 11 - Jinkai New Energy is planning to transfer 51% of its subsidiary's equity to introduce strategic investors [31] - Huafeng Technology has reduced its fundraising target for a private placement to no more than 972 million yuan [32] - Mindray Medical's chairman plans to increase his stake in the company by 200 million yuan [33] Group 12 - Zhongman Petroleum's shareholders plan to reduce their holdings by up to 3% [35] - Innovation New Materials' shareholder intends to reduce their stake by up to 1% [37] - Guangdong Construction has signed a framework agreement to establish a quality testing base in Linzhi Economic Development Zone [39]

Core Viewpoint - The company plans to establish a subsidiary in Singapore and a subsidiary in Malaysia with an investment of up to 70 million USD (approximately 500 million RMB) to enhance strategic cooperation with international clients and integrate into the global aviation and medical orthopedic joint supply chain [1] Group 1 - The investment aims to deepen the company's strategic collaboration with international clients [1] - The initiative is a key measure to respond flexibly to international customer demands and address global aviation supply chain challenges [1] - The company seeks to explore growth potential in the medical orthopedic joint business to enhance its global market competitiveness and risk resilience [1]

无锡航亚科技股份有限公司 证券代码：688510 证券简称：航亚科技 公告编号：2025-041 关于对外投资暨设立海外子公司及孙公司的公告 投资标的名称：无锡航亚科技股份有限公司（以下简称"公司"或"航亚科 技"）拟在新加坡设立子公司"Hyatech Investments Singapore PTE. LTD." （暂定 名，最终以当地主管机关核准登记名称为准，下同）、在马来西亚设立孙公司 "Hyatech (Malaysia) SDN. BHD."。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 拟投资金额：不超过 7,000 万美元（折合人民币约 50,000 万元），以公司 自有（自筹）资金出资（实际投资金额以中国及当地主管部门批准金额为准）。 重要内容提示： 本次对外投资不构成关联交易，亦不构成《上市公司重大资产重组管理 办法》规定的重大资产重组。 风险提示：本次对外投资尚需履行国内有关部门的境外投资审批或备案 手续，以及新加坡、马来西亚当地投资许可和企业登记等审批或登记程序，能否 顺利实施存在一定的不确定性；本 ...

Core Viewpoint - The company plans to establish subsidiaries in Singapore and Malaysia to enhance its strategic layout and expand its overseas market presence, with an investment of up to 70 million USD (approximately 500 million RMB) [1] Group 1 - The establishment of "Hyatech Investments Singapore PTE. LTD." in Singapore and "Hyatech (Malaysia) SDN. BHD." in Malaysia is part of the company's strategy to optimize its business operations [1] - The investment is aimed at improving the company's overall competitiveness and aligns with its long-term development plans [1] - The strategic significance of this investment is expected to have a positive impact on the company's operations [1]

Core Viewpoint - The company plans to establish a subsidiary in Singapore and a branch in Malaysia with an investment of up to 70 million USD (approximately 500 million RMB) to enhance strategic cooperation with international clients and integrate into the global aviation and orthopedic medical supply chain [1] Group 1 - The investment aims to deepen the company's strategic collaboration with international clients [1] - The initiative is a key measure to respond to global aviation supply chain challenges [1] - The company seeks to tap into the growth potential of the orthopedic medical business [1] Group 2 - The establishment of the subsidiaries will allow the company to be closer to international markets [1] - The move is intended to enable more flexible responses to international client demands [1] - The investment is expected to enhance the company's global market competitiveness and risk resilience [1]